AU2003283938A1 - Use of certain compounds in treatment of obesity - Google Patents

Use of certain compounds in treatment of obesity

Info

Publication number
AU2003283938A1
AU2003283938A1 AU2003283938A AU2003283938A AU2003283938A1 AU 2003283938 A1 AU2003283938 A1 AU 2003283938A1 AU 2003283938 A AU2003283938 A AU 2003283938A AU 2003283938 A AU2003283938 A AU 2003283938A AU 2003283938 A1 AU2003283938 A1 AU 2003283938A1
Authority
AU
Australia
Prior art keywords
obesity
treatment
certain compounds
compounds
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003283938A
Other languages
English (en)
Inventor
Jan-Olov Jansson
Claes Ohlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDOCRINE HEALTH I GOTEBORG AB
Original Assignee
ENDOCRINE HEALTH I GOTEBORG AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203642A external-priority patent/SE526153C2/sv
Application filed by ENDOCRINE HEALTH I GOTEBORG AB filed Critical ENDOCRINE HEALTH I GOTEBORG AB
Publication of AU2003283938A1 publication Critical patent/AU2003283938A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003283938A 2002-12-06 2003-12-08 Use of certain compounds in treatment of obesity Abandoned AU2003283938A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0203642A SE526153C2 (sv) 2002-12-06 2002-12-06 Användning av statiner vid behandling av fetma
SE0203642-4 2002-12-06
SE0301846-2 2003-06-25
SE0301846A SE0301846D0 (sv) 2002-12-06 2003-06-25 Use of certain compounds in treatment of obesity
PCT/SE2003/001913 WO2004052368A1 (fr) 2002-12-06 2003-12-08 Utilisation de certains composes dans le traitement de l'obesite

Publications (1)

Publication Number Publication Date
AU2003283938A1 true AU2003283938A1 (en) 2004-06-30

Family

ID=27667650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003283938A Abandoned AU2003283938A1 (en) 2002-12-06 2003-12-08 Use of certain compounds in treatment of obesity

Country Status (3)

Country Link
AU (1) AU2003283938A1 (fr)
SE (1) SE0301846D0 (fr)
WO (1) WO2004052368A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524175C (fr) 2003-04-28 2016-06-14 Sankyo Company Limited Composition activant l'aptitude a consommer du sucre
ES2421520T3 (es) 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
US20100048595A1 (en) * 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
FR2987270A1 (fr) * 2012-02-29 2013-08-30 Agronomique Inst Nat Rech Produit de combinaison pour le traitement du surpoids et/ou l'amelioration de la silhouette
EP3355882A1 (fr) * 2015-10-01 2018-08-08 Kythera Biopharmaceuticals, Inc. Compositions comprenant une statine pour une utilisation dans des procédés d'adipolyse

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug

Also Published As

Publication number Publication date
SE0301846D0 (sv) 2003-06-25
WO2004052368A1 (fr) 2004-06-24

Similar Documents

Publication Publication Date Title
AU2003298043A1 (en) Surface treatment of medical device
IL218909A0 (en) Treatment of diabetes
AU2003281978A8 (en) Compounds for use in treating obesity
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
GB0324761D0 (en) Use of compounds in therapy
AU2003208100A1 (en) Water treatment device
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1682136A4 (fr) Composes therapeutiques et utilisations correspondantes
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AUPS328002A0 (en) Water treatment
AU2003260778A1 (en) Treatment of pipes
AU2002359177A1 (en) Use of interleukin-6 for treatment of obesity
GB0207410D0 (en) Compounds and their therapeutic use
AU2002952086A0 (en) Treatment of osteoarthritis
AU2003283938A1 (en) Use of certain compounds in treatment of obesity
AU2003270615A1 (en) Treatment of steatosis using hyperthermia
AU2003207315A1 (en) Treatment of muscle damage
AU2003240446A1 (en) Use of mob-5 in pain
AU2003274359A1 (en) Treatment of fluids
GB0221712D0 (en) Methods of treatment
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
AU2003215606A1 (en) The use of a benzenesulfonamide compound in the treatment of obesity
GB0329357D0 (en) Treatment of materials
AU2003208809A1 (en) Treatment of neuroblastoma
AU2003243215A1 (en) Treatment for human papillomavirus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase